Product Name: TAO1 (178-184) pS181
Product Number: PE-04ALF99
Size: 200 µg      Price:42.00
1 mg      $US84.00
5 mg      185.00
Peptide Name: TAO1 (178-184) pS181

Product Use: Services as a blocking peptide for use with the TAO1-pS181 rabbit polyclonal antibody (Cat. No.: AB-PK826) that is also available from Kinexus. This phosphopeptide may also be useful as a substrate for screening the phosphatase activity of protein phosphatases. The peptide sequence is located in the protein kinase catalytic domain activation T loop region between subdomains VII and VIII. S181 phosphorylation is predicted to be stimulatory for phosphotransferase activity.

Peptide Production Method: Solid-phase peptide synthesis

Peptide Origin: Homo sapiens

Peptide Sequence: PAN-pS-FVG

Peptide Modifications N Terminus: Free amino

Peptide Modifications C Terminus: βAla-Cys

Peptide Modifications Other: Phosphorylated

Peptide Molecular Mass Calculated: 944.94 Da

Peptide Purity Percent after Synthesis and Purification: >95

Peptide Appearance: White powder

Peptide Form: Solid

Storage Conditions: -20°C

Related Product 1: TAO1 - pS181 phosphosite-specific antibody (Cat. No.: AB-PK826)

Scientific Background: TAO1 (MAP3K16, TAOK1) is a protein-serine/threonine kinase of the STE group and STE20 family. It is involved in various processes such as p38/MAPK14 stress-activated MAPK cascade, DNA damage response and regulation of cytoskeleton stability. It phosphorylates MAP2K3, MAP2K6 and MARK2, and acts as an activator of the p38 (MAPK14) stress-activated MAPK cascade by phosphorylation and activation of the upstream MKK3 and MKK6 kinases. It is involved in G protein-coupled receptor signalling to p38 (MAPK14). In response to DNA damage, it is involved in the G2/M transition DNA damage checkpoint by activating the p38 (MAPK14) stress-activated MAPK cascade, probably by mediating phosphorylation of MKK3 (MAP2K3) and MKK6 (MAP2K6). It serves as a regulator of cytoskeleton stability by phosphorylating MARK2 at T208, leading to its activation and subsequent phosphorylation and detachment of MAPT/TAU from microtubules. It also regulates apoptotic morphological changes, including cell contraction, membrane blebbing and apoptotic bodies formation via activation of the JNK (MAPK8) cascade.